Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75

Benzinga Newsdesk www.benzinga.com Neutral 66.2%

Neg 0% Neu 66.2% Pos 0%

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $75.